Key Takeaways:
Ribo has launched its Hong Kong IPO, boasting the world's first siRNA drug targeting thrombotic diseases as one of its core products
Its model of "China discovery and development + European clinical development and registration" lays a foundation for synchronous drug development in China and Europe
Ribonucleic acid, or RNA, has emerged as a hot new field after mRNA and miRNA discoveries won Nobel Prizes in 2023 and 2024, respectively, drawing attention to its scientific value and industrial potential. In the medical field, RNA-based small nucleic acid drugs, by virtue of their broad target selection scope, higher clinical success rates, and durable effects, are poised to become leaders driving a third wave of highly targeted new drugs, following small-molecule drugs and antibody therapeutics. Against that backdrop, international investors will soon have a chance to buy into China's leading company within the small nucleic acid drugs sector.
Suzhou Ribo Life Science Co. Ltd., with 18 years of experience in small nucleic acid drugs, is launching its IPO in Hong Kong, positioning itself as a world leading player focused on small interfering RNA therapeutics, or siRNA.
After passing its listing hearing last month, the company officially launched its Hong Kong IPO on Dec. 31, aiming to raise about HK$1.59 billion ($205 million) by selling 27.5 million shares for HK$57.97 each. Heavyweight underwriters CICC and Citigroup are joint sponsors, signaling strong interest from both domestic Chinese and international investors.
A subscription period for the shares will run through Jan. 6 with a trading debut scheduled for Jan 9.
Founded in 2007, Ribo has long focused on small nucleic acid drug development, especially for siRNA therapeutics, giving it one of the world's largest siRNA drug pipelines. The company currently has seven self-developed drug assets in the clinical trial stages, targeting seven indications across cardiovascular, metabolic, kidney and liver diseases. Among these, four are in Phase Two clinical trials, with more than ...
